Spinal Cord Stimulators (SCS) are medical devices designed to manage chronic pain by delivering electrical impulses to the spinal cord. These impulses interfere with the transmission of pain signals to the brain, providing relief to individuals suffering from various conditions, such as failed back surgery syndrome, complex regional pain syndrome (CRPS), and neuropathic pain.
Abbott Launched the Proclaim™ SCS System, featuring smaller implanted components and wireless charging technology for improved patient comfort and convenience.Received Medicare coverage for SCS therapy for chronic back pain due to failed back surgery syndrome, potentially increasing patient access to this treatment option.
Boston Scientific Expanded its SCS portfolio with the launch of the Intellis™ SCS System, offering advanced programming capabilities and data-driven insights for personalized pain management. Partnered with Vertifect, a developer of spinal disc replacement devices, to explore potential synergies and improve pain management outcomes for patients with complex pain conditions.
Medtronic Received FDA approval for its RestoreSensor™ SCS System with Sensible™ Technology, featuring intelligent algorithms that automatically adjust stimulation parameters based on individual patient needs and activities. Announced a collaboration with the University of California, San Francisco, to develop and validate new applications for SCS therapy beyond chronic pain management, such as treating spasticity and Parkinson's disease symptoms.
Spinal Cord Stimulator Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)